Until recently, interest in renal function has focused on impairment to limit drug toxicity and increase medication safety. Augmented renal clearance (ARC) has been increasingly studied in multiple patient populations, including oncology, and could lead to decreased drug efficacy from faster elimination resulting in subtherapeutic concentrations. This scoping review sought to summarize ARC literature in cancer and identify areas of research to better inform pharmacy practitioners.
Data Sources
Electronic databases were searched for English articles related to augmented/enhanced renal function/clearance following a framework for scoping reviews.
Data Synthesis
Fourteen articles were analyzed, divided according to article objective: descriptive studies or ARC’s impact on pharmacokinetics/pharmacodynamics. ARC was most defined as creatinine clearance >130 mL/min/1.73 m2, reported in 10%-100% of patients. Febrile neutropenia in adult and pediatric patients, and age <50-65 years, hematologic malignancy, and lower serum creatinine in adult patients were notable risk factors for ARC. The impact of ARC has only been evaluated with antimicrobial agents consistently resulting in lower than anticipated trough levels. Identified gaps include: elucidation of ARC’s mechanism and associated biomarkers, an inclusive ARC definition for relative renal enhancement, and study of additional drug classes to ascertain the breadth of ARC impact on drug therapy.
Conclusions
ARC is proving to be a frequent phenomenon in patients with cancer which pharmacists could play a vital role. Further research is needed to better understand the impact of ARC in patient care and a potential need to stage ARC based on degree of renal enhancement to establish specific drug dosing recommendations.
UdyAABaptistaJPLimNL, et al. Augmented renal clearance in the ICU: Results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42(3):520-527. doi:10.1097/CCM.0000000000000029.
UdyAARobertsJALipmanJ. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011;7(9):539-543. doi:10.1038/nrneph.2011.92.
4.
UdyAARobertsJAShorrAFBootsRJLipmanJ. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk patients. Crit Care. 2013;17(1):R35. doi:10.1186/cc12544.
5.
TrögerUDrustAMartens-LobenhofferJTanevIBraun-DullaeusRCBode-BögerSM. Decreased meropenem levels in intensive care unit patients with augmented renal clearance: Benefit of therapeutic drug monitoring. Int J Antimicrob Agents. 2012;40(4):370-372. doi:10.1016/j.ijantimicag.2012.05.010.
6.
BaptistaJPSousaEMartinsPJPimentelJM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents. 2012;39(5):420-423. doi:10.1016/j.ijantimicag.2011.12.011.
7.
UdyAARobertsJABootsRJPatersonDLLipmanJ. Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000.
8.
UdyAARobertsJALipmanJ. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39(12):2070-2082. doi:10.1007/s00134-013-3088-4.
9.
UdyAAVargheseJMAltukroniM, et al. Subtherapeutic initial β-lactam concentrations in select critically Ill patients: Association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30-39. doi:10.1378/chest.11-1671.
10.
UdyAARobertsJALipmanJ. Augmented renal clearance: Unraveling the mystery of elevated antibiotic clearance. In: VincentJ, ed, Intensive Care Medicine. New York, NY: Springer New York; 2010:495-506. doi:10.1007/978-1-4419-5562-3_46.
11.
UdyAARobertsJADe WaeleJJPatersonDLLipmanJ. What’s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39(6):455-457. doi:10.1016/j.ijantimicag.2012.02.010.
12.
UdyAADe WaeleJJLipmanJ. Augmented renal clearance and therapeutic monitoring of β-lactams. Int J Antimicrob Agents. 2015;45(4):331-333. doi:10.1016/j.ijantimicag.2014.12.020.
13.
TriccoACLillieEZarinW, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16(1):1-10. doi:10.1186/S12874-016-0116-4/TABLES/4.
14.
ArkseyHO’MalleyL. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005;8(1):19-32. doi:10.1080/1364557032000119616.
15.
TriccoACLillieEZarinW, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169:467-473. doi:10.7326/M18-0850.
16.
AltmanD. Practical Statistics for Medical Research. New York, NY: Chapman & Hall/CRC Press; 1999.
HiraiKIshiiHShimoshikiryoT, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. Ther Drug Monit. 2016;38(6):706-710. doi:10.1097/FTD.0000000000000346.
19.
NazerLKamalYAbusaraA. Prevalence and predictors of augmented renal clearance in critically ill patients with cancer. Crit Care Med. 2020;48(11):681.
20.
SaitoKKamioSItoKSuzukiNAbeKGotoT. A simple scoring method to predict augmented renal clearance in haematologic malignancies. J Clin Pharm Therapeut. 2020;45(5):1120-1126. doi:10.1111/jcpt.13193.
21.
VermisKSteelEVandenbrouckeJ. Prevalence of augmented renal clearance in haematological patients and the impact on vancomycin dosing. J Oncol Pharm Pract. 2014;20(3):7-31. doi:10.1177/1078155214523700.
22.
CojuttiPGCandoniARamos-MartinV, et al. Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. J Antimicrob Chemother. 2017;72(8):2342-2350. doi:10.1093/jac/dkx140.
23.
IzumisawaTKanekoTSomaM, et al. Augmented renal clearance of vancomycin in hematologic malignancy patients. Biol Pharm Bull. 2019;42(12):2089-2094. doi:10.1248/bpb.b19-00652.
24.
CojuttiPGLazzarottoDCandoniA, et al. Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study. J Antimicrob Chemother. 2020;75(10):3029-3037. doi:10.1093/jac/dkaa267.
25.
YasuTKonumaTOiwa-MonnaM, et al. Lower vancomycin trough levels in adults undergoing unrelated cord blood transplantation. Leuk Lymphoma. 2020;62:348-357. doi:10.1080/10428194.2020.1834096.
26.
BautersTDe MoerlooseBRaesA, et al. Augmented renal clearance associated with vancomycin clearance in pediatric hemato-oncology and stem cell transplantation patients. Biol Blood Marrow Transplant. 2019;25(3):S275-S276. doi:10.1016/j.bbmt.2018.12.340.
27.
HiraiKIharaSKinaeA, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38(3):393-397. doi:10.1097/FTD.0000000000000270.
28.
LvCLuJJChenM, et al. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children. J Clin Pharm Therapeut. 2020;45(6):1278-1287. doi:10.1111/jcpt.13206.
29.
ShimamotoYMizunoTVerstegenRAllenUItoS. Vancomycin pharmacokinetics in pediatric patients with febrile neutropenia: Effect of augmented renal clearance. Clin Pharmacol Ther. 2020;107(1):S12.
30.
SimeFBHahnUWarnerMS, et al. Using population pharmacokinetic modeling and monte carlo simulations to determine whether standard doses of piperacillin in piperacillin-tazobactam regimens are adequate for the management of febrile neutropenia. Antimicrob Agents Chemother. 2017;61(11):e00311-e00317. doi:10.1128/AAC.00311-17.
31.
Bilbao-MeseguerIRodríguez-GascónABarrasaHIslaASolinísMÁ. Augmented renal clearance in critically ill patients: A systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7.
32.
MorbitzerKAJordanJDDehneKADurrEAOlm-ShipmanCMRhoneyDH. Enhanced renal clearance in patients with hemorrhagic stroke. Crit Care Med. 2019;47(6):800-808. doi:10.1097/CCM.0000000000003716.
33.
SimeFBRobertsJAJeffreeRL, et al. Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance. Clin Pharmacokinet;60(5):655-664. doi:10.1007/s40262-020-00979-8.
WellsMAMorbitzerKRhoneyDH. Evaluation of the accuracy of standard renal function equations in critically ill patients with subarachnoid hemorrhage. Neurocritical Care. 2020;32(3):828-835. doi:10.1007/s12028-019-00854-w.
37.
BaptistaJSilvaNCostaE, et al. Identification of the critially ill patient with augmented renal clearance: Make do with what you have. Intensive Care Med. 2014;40(1):S110. doi:10.1007/s00134-013-3451-5.
38.
BarlettaJFMangramAJByrneM, et al. Identifying augmented renal clearance in trauma patients: Validation of the augmented renal clearance in trauma intensive care scoring system. J Trauma Acute Care Surg. 2017;82(4):665-671. doi:10.1097/TA.0000000000001387.
39.
AvedissianSNBradleyEZhangD, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients. Pediatr Crit Care Med. 2017;18(9):e388-e394. doi:10.1097/PCC.0000000000001228.
40.
FreifeldAGBowEJSepkowitzKA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/cir073.
41.
RamsyAAmalAFotihSSelwiW. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res. 2016;5(3):00165. doi:10.15406/jcpcr.2016.05.00165.
42.
HuttnerAVon DachERenzoniA, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Int J Antimicrob Agents. 2015;45(4):385-392. doi:10.1016/j.ijantimicag.2014.12.017.
43.
ClausBOMHosteEAColpaertKRobaysHDecruyenaereJDe WaeleJJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013;28(5):695-700. doi:10.1016/j.jcrc.2013.03.003.
44.
UdyAADulhuntyJMRobertsJA, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: A nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents. 2017;49(5):624-630. doi:10.1016/j.ijantimicag.2016.12.022.
45.
Tomasa-IrriguibleTMMartínez-VegaSMor-MarcoEHerraiz-RuizARaguer-PardoLCubells-LarrosaC. Low molecular weight heparins in COVID-19 patients: Beware of augmented renal clearance. Crit Care. 2020;24(325):1-2. doi:10.1186/s13054-020-03058-3.
46.
MahmoudSHShenC. Augmented renal clearance in critical illness: An important consideration in drug dosing. Pharmaceutics. 2017;9(3):36. doi:10.3390/pharmaceutics9030036.
47.
Tomasa-IrriguibleTM. Augmented renal clearance: Much more is better?Med Intensiva. 2018;42(8):500-503. doi:10.1016/j.medin.2018.02.004.
48.
CarrieCLannouARubinSDe CoursonHPetitLBiaisM. Augmented renal clearance in critically ill trauma patients: A pathophysiologic approach using renal vascular index. Anaesth Crit Care Pain Med. 2019;38(4):371-375. doi:10.1016/j.accpm.2018.12.004.
49.
CarrieCBentejacMCottenceauV, et al. Association between augmented renal clearance and clinical failure of antibiotic treatment in brain-injured patients with ventilator-acquired pneumonia: A preliminary study. Anaesthesia Crit care pain Med. 2018;37(1):35-41. doi:10.1016/j.accpm.2017.06.006.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
